Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib.

ABSTRACT:

Background

Axitinib, an inhibitor of vascular endothelial growth factor (VEGF) receptors, is approved as second-line treatment for advanced renal cell carcinoma (RCC). Agents targeting the VEGF pathway may induce renal toxicities, which may be influenced by pre-existing renal dysfunction.

Objective

The objective was to characterize axitinib pharmacokinetics and safety in patients with renal impairment.

Patients and methods

Effect of renal function (baseline creatinine clearance [CrCL]) on axitinib clearance was evaluated in a population pharmacokinetic model in 207 patients with advanced solid tumors who received a standard axitinib starting dose, and in 383 healthy volunteers. Axitinib safety according to baseline CrCL was assessed in previously treated patients with

SUBMITTER: Chen Y 

PROVIDER: S-EPMC5568082 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature